You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,161,978


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,161,978
Title:Methods of treatment of pterygium using an anti-VEGF agent
Abstract: Methods for treating pterygium recurrence following pterygiectomy, and for treating keloid recurrence, following surgical removal of the keloid, are disclosed. The methods include administering an anti-VEGF agent (e.g., antibody (e.g., bevacizumab) or small molecule inhibitor of VEGF signaling), or a combination therapy that includes co-administering an anti-VEGF agent, with an anti-inflammatory steroid and/or a non-steroidal anti-inflammatory drug (NSAID) to a subject.
Inventor(s): Pham; Randal Tanh Hoang (San Jose, CA)
Assignee:
Application Number:14/261,198
Patent Claims:1. A method for treating pterygium recurrence comprising administering to an affected eye of a subject in need of such treatment (1) an anti-VEGF-A agent; and one or both of (2) an anti-inflammatory steroid and (3) a non-steroidal anti-inflamatory drug (NSAID).

2. The method of claim 1, wherein the anti-VEGF agent is the antibody bevacizumab.

3. The method of claim 2, wherein the amount of bevacizumab administered is about 2.5 mg.

4. The method of claim 1, wherein the anti-VEGF agent is injected at a site of new blood vessel growth in the affected eye.

5. The method of claim 1, wherein the anti-inflammatory steroid is selected from the group consisting of prednisolone acetate, difluprednate, or triamcinolone acetonide.

6. The method of claim 1, wherein the NSAID is selected from the group consisting of diclofenac, ketorolac, bromfenac and nepafenac.

7. The method of claim 1, wherein the anti-VEGF agent is administered at least once before the anti-inflammatory steroid or the NSAID or both are administered.

8. The method of claim 1, wherein the anti-inflammatory steroid or the NSAID is administered to the affected eye of the subject at least once before the anti-VEGF agent is administered.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.